Vanguard Global Advisers’s Alto Neuroscience ANRO Stock Holding History

Vanguard Global Advisers’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$281K	Hold	10,649	–	–	﹤0.01%	2361
2026 Q1	$239K	Buy	+10,649	New	+$197K	﹤0.01%	2351

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Global Advisers's ANRO Position: Q2 2026 in Review

Vanguard Global Advisers held its Alto Neuroscience (ANRO) position steady in Q2 2026 at 10,649 shares worth $281K. The position accounts for ﹤0.01% of the portfolio, ranked #2361.

Vanguard Global Advisers first reported a position in ANRO in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

Vanguard Global Advisers held 10,649 shares of Alto Neuroscience worth $281K as of Q2 2026.
Vanguard Global Advisers left its Alto Neuroscience share count unchanged in Q2 2026.
Alto Neuroscience made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2361 holding.
Vanguard Global Advisers first reported a position in Alto Neuroscience in Q1 2026 and has held it in 2 quarters since.
114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.